PROCEPT BioRobotics Announces Category I CPT Code for Aquablation Therapy

Strategic Insights -

The announcement has marked a significant milestone for PROCEPT BioRobotics, the urology community, and patients suffering from benign prostatic hyperplasia (BPH). The assignment of a Category I CPT code for Aquablation therapy recognizes its clinical value and widespread use, paving the way for broader patient access to this treatment. As Sham Shiblaq, chief commercial officer of PROCEPT BioRobotics, stated, "This transition recognizes the clinical value and widespread use of Aquablation therapy as we continue to make progress toward becoming the BPH surgical standard of care."

Key Takeaways:

  • PROCEPT BioRobotics has announced that Aquablation therapy has been assigned a Category I code effective January 1, 2026.
  • The Category I CPT code 52XX1 will replace Category III CPT code 0421T as the primary code for Aquablation therapy.
  • The Category I code will further support surgeon adoption and broaden patient access to a treatment that delivers durable symptom relief with a low risk of sexual side effects.
  • The new CPT Category I Code 52XX1 was assigned a 2026 national Medicare physician proposed payment of 16.14 total RVUs, translating to an approximate national average of $540.
  • This compares to TURP, which was assigned 15.82 total RVUs, translating to an approximate national average of $529.
  • The Proposed Rule release is followed by a public comment period that will close in September 2025 and will culminate in CMS' release of the Final Rule, which is expected to be announced in November 2025 for implementation on January 1, 2026.
  • The Proposed Rule is subject to change.
  • Aquablation therapy is the first and only ultrasound-guided, robotic-assisted, heat-free waterjet therapy for the treatment of BPH.
  • The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy.
  • PROCEPT BioRobotics has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications supporting the benefits and clinical advantages of Aquablation therapy.

Statistics:

  • 2026 national Medicare physician proposed payment for Category I CPT code 52XX1: 16.14 total RVUs ($540)
  • 2026 national Medicare physician proposed payment for TURP: 15.82 total RVUs ($529)
  • Number of men in the United States impacted by BPH: approximately 40 million
  • Number of peer-reviewed publications supporting Aquablation therapy: over 150
  • Year the Category I CPT code for Aquablation therapy will be effective: January 1, 2026

Sources:

  • PROCEPT BioRobotics Corporation press release, July 14, 2025
  • Medicare Proposed Physician Fee Schedule (PFS) for 2026
  • Centers for Medicare and Medicaid Services (CMS) website
  • PROCEPT BioRobotics Corporation website
  • Peer-reviewed publications supporting Aquablation therapy (over 150)